160384-37-2 Usage
Uses
Used in Pharmaceutical Industry:
3-[4-[2-(2,5-Dichloro-4-nitrophenyl)ethenyl]-1-piperazinyl]-1,2-benzisothiazole is used as an intermediate in the synthesis of antipsychotic agents, specifically for the production of Ziprasidone (Z485000). Its role in the development of this medication is crucial, as it contributes to the treatment of various psychiatric disorders and conditions.
As an intermediate in the synthesis of antipsychotic agents, 3-[4-[2-(2,5-Dichloro-4-nitrophenyl)ethenyl]-1-piperazinyl]-1,2-benzisothiazole plays a vital role in the pharmaceutical industry. Its chemical properties and structure enable the creation of effective medications that can help manage and treat mental health conditions. The compound's red solid form also provides a distinctive characteristic that can be useful in identifying and handling it during the synthesis process.
Check Digit Verification of cas no
The CAS Registry Mumber 160384-37-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,0,3,8 and 4 respectively; the second part has 2 digits, 3 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 160384-37:
(8*1)+(7*6)+(6*0)+(5*3)+(4*8)+(3*4)+(2*3)+(1*7)=122
122 % 10 = 2
So 160384-37-2 is a valid CAS Registry Number.
160384-37-2Relevant academic research and scientific papers
A novel synthesis of the antipsychotic agent ziprasidone
Urban, Frank J.,Breitenbach, Ralph,Gonyaw, Dianne
, p. 1629 - 1638 (2007/10/03)
A new synthesis of the antipsychotic ziprasidone from 2,5-dichloro-4-nitrotoluene 3 is presented. The nitro group in 3 was used to activate the orthochlorine for displacement and the methyl group for enamine formation and introduction of the piperazinyl moiety.
Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
-
, (2008/06/13)
A process for preparing the compound of the formula STR1 which comprises treating a compound of the formula STR2 wherein R2 is hydrogen, CN or CO2 R1 and R1 is hydrogen or (C1 -C6)alkyl with a reducing agent with the proviso that when R2 is CN or CO2 R1 and R1 is (C1 -C6)alkyl the product of the reduction is heated with an acid. Compounds of formula II wherein R2 is CN or CO2 R1 and R1 is (C1 -C6)alkyl or R2 is hydrogen and R1 is (C1 -C6)alkyl or hydrogen. The compound of formula VII R1 is (C1 -C6)alkyl. The compound of formula III. The compound of formula I is useful in the treatment of psychotic disorders.
